Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation

Background. The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Keir McCutcheon, Maarten Vanhaverbeke, Jérémie Dabin, Ruben Pauwels, Werner Schoonjans, Walter Desmet, Johan Bennett
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Journal of Interventional Cardiology
Online Access:http://dx.doi.org/10.1155/2021/3146104
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850157656029790208
author Keir McCutcheon
Maarten Vanhaverbeke
Jérémie Dabin
Ruben Pauwels
Werner Schoonjans
Walter Desmet
Johan Bennett
author_facet Keir McCutcheon
Maarten Vanhaverbeke
Jérémie Dabin
Ruben Pauwels
Werner Schoonjans
Walter Desmet
Johan Bennett
author_sort Keir McCutcheon
collection DOAJ
description Background. The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods. We performed a prospective, randomized-controlled study comparing operator radiation dose during CTO PCI (n = 60) with or without pelvic MXPDs. The primary outcomes were the difference in first operator radiation dose (μSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. The effectiveness of MXPD in CTO PCI was compared with non-CTO PCI using a patient-level pooled analysis with a previously published non-CTO PCI randomized study. Results. The use of the MXPD was associated with a 37% reduction in operator dose (weighted median dose 26.0 (IQR 10.00–29.47) μSv in the drape group versus 41.8 (IQR 30.82–60.59) μSv in the no drape group; P<0.001) and a 60% reduction in relative operator dose (median dose 3.5 (IQR 2.5–5.4) E/DAPx10−3 in the drape group versus 8.6 (IQR 4.2–12.5) E/DAPx10−3 in the no drape group; P=0.001). MXPD was equally effective in reducing operator dose in CTO PCI compared with non-CTO PCI (P value for interaction 0.963). Conclusions. The pelvic MAVIG X-ray protective drape significantly reduced CTO operator radiation dose. This trial is clinically registered with https://www.clinicaltrials.gov (unique identifier: NCT04285944).
format Article
id doaj-art-349a019cfee647b0814f31bd7b426480
institution OA Journals
issn 1540-8183
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Journal of Interventional Cardiology
spelling doaj-art-349a019cfee647b0814f31bd7b4264802025-08-20T02:24:05ZengWileyJournal of Interventional Cardiology1540-81832021-01-01202110.1155/2021/3146104Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator RadiationKeir McCutcheon0Maarten Vanhaverbeke1Jérémie Dabin2Ruben Pauwels3Werner Schoonjans4Walter Desmet5Johan Bennett6Department of Cardiovascular MedicineDepartment of Cardiovascular MedicineBelgian Nuclear Research CentreDepartment of Cardiovascular MedicineBelgian Nuclear Research CentreDepartment of Cardiovascular MedicineDepartment of Cardiovascular MedicineBackground. The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods. We performed a prospective, randomized-controlled study comparing operator radiation dose during CTO PCI (n = 60) with or without pelvic MXPDs. The primary outcomes were the difference in first operator radiation dose (μSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. The effectiveness of MXPD in CTO PCI was compared with non-CTO PCI using a patient-level pooled analysis with a previously published non-CTO PCI randomized study. Results. The use of the MXPD was associated with a 37% reduction in operator dose (weighted median dose 26.0 (IQR 10.00–29.47) μSv in the drape group versus 41.8 (IQR 30.82–60.59) μSv in the no drape group; P<0.001) and a 60% reduction in relative operator dose (median dose 3.5 (IQR 2.5–5.4) E/DAPx10−3 in the drape group versus 8.6 (IQR 4.2–12.5) E/DAPx10−3 in the no drape group; P=0.001). MXPD was equally effective in reducing operator dose in CTO PCI compared with non-CTO PCI (P value for interaction 0.963). Conclusions. The pelvic MAVIG X-ray protective drape significantly reduced CTO operator radiation dose. This trial is clinically registered with https://www.clinicaltrials.gov (unique identifier: NCT04285944).http://dx.doi.org/10.1155/2021/3146104
spellingShingle Keir McCutcheon
Maarten Vanhaverbeke
Jérémie Dabin
Ruben Pauwels
Werner Schoonjans
Walter Desmet
Johan Bennett
Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation
Journal of Interventional Cardiology
title Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation
title_full Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation
title_fullStr Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation
title_full_unstemmed Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation
title_short Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation
title_sort efficacy of mavig x ray protective drapes in reducing cto operator radiation
url http://dx.doi.org/10.1155/2021/3146104
work_keys_str_mv AT keirmccutcheon efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation
AT maartenvanhaverbeke efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation
AT jeremiedabin efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation
AT rubenpauwels efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation
AT wernerschoonjans efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation
AT walterdesmet efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation
AT johanbennett efficacyofmavigxrayprotectivedrapesinreducingctooperatorradiation